Treatment of metastatic hormone dependent breast cancer with combination palbociclib and letrozol – case report
01/2020 Special Edition
MUDr. Věra Benešová
Komplexní onkologické centrum nemocnice Jihlava
Anti-tumor effect of CDK4/6 inhibitors in combination with hormone therapy significantly prolong progression free survival with prolongation time of lifetime. The use of this combination therapy in routine clinical practice fundamentally changes the treatment options of our patients.
metastatic hormone dependent breast cancer, aromatase inhibitor letrozole, CDK4/6 inhibitor, palbociclib, Ibrance
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...